authors
- Zhang, Fengchun
- Chu, Myron
- Curtis, Paula
- DeRose, Kathleen
- Kurrasch, Regina
- Lowe, Jenny
- Meizlik, Paige
- Roth, David A
- Zheng, Jie
- Li, Yang
- Wang, Guochun
- Wang, Mingjun
- Su, Yin
- Gu, Jieruo
- Li, Xingfu
- Bass, Damon
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
- Overview
- Research
- Identity
- Additional Document Info
- View All